Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

UMMS Affiliation

Department of Medicine, Division of Infectious Diseases and Immunology; Laboratory of Nucleic Acid Vaccines; Center for Infectious Disease and Vaccine Research

Publication Date


Document Type



Immunity | Immunology and Infectious Disease | Immunology of Infectious Disease | Infectious Disease


An optimally effective AIDS vaccine would likely require the induction of both neutralizing antibody and cell-mediated immune responses, which has proven difficult to obtain in previous clinical trials. Here we report on the induction of human immunodeficiency virus type-1 (HIV-1)-specific immune responses in healthy adult volunteers that received the multi-gene, polyvalent, DNA prime-protein boost HIV-1 vaccine formulation, DP6-001, in a Phase I clinical trial. Robust cross-subtype HIV-1 specific T cell responses were detected in IFN-gamma ELISPOT assays. Furthermore, we detected high titer serum antibody responses that recognized a wide range of primary HIV-1 Env antigens and also neutralized pseudotyped viruses that express the primary Env antigens from multiple HIV-1 subtypes. These findings demonstrate that the DNA prime-protein boost approach is an effective immunization method to elicit both humoral and cell-mediated immune responses in humans, and that a polyvalent Env formulation could generate broad immune responses against HIV-1 viruses with diverse genetic backgrounds.


Vaccine. 2008 Jul 23;26(31):3947-57.

Journal/Book/Conference Title



Republication of: Vaccine. 2008 Feb 20;26(8):1098-110. Epub 2008 Jan 10. doi: 10.1016/j.vaccine.2007.12.024. See: http://escholarship.umassmed.edu/oapubs/2057/

Related Resources

Link to Article in PubMed

PubMed ID